Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation

Clinical Transplantation

Volumn 21, Issue 3, 2007, Pages 377-384

  Campbell, Mical S ^a   Rai, Jitha ^a   Kozin, Elliott ^a   Bloom, Roy D ^a   Markmann, James F ^a   Olthoff, Kim M ^a   Shaked, Abraham ^a   Reddy, Rajender K ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Creatinine; Immunosuppression; Liver transplantation; Renal insufficiency; Tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CANCER RECURRENCE; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; ENCEPHALITIS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; KIDNEY DYSFUNCTION; KIDNEY TRANSPLANTATION; LEG EDEMA; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RENAL PROTECTION; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; TREMOR;

ADULT; CALCINEURIN; CARCINOMA, HEPATOCELLULAR; CREATININE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LINEAR MODELS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS;

EID: 34248138502     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00653.x     Document Type: Article

References (20)

1. Post DJ, Douglas DD, Mulligan DC. Immunosuppression in liver transplantation. Liver Transpl 2005: 11: 1307.
2. Gonwa TA, Mai ML, Melton LB et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001: 72: 1934.
3. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003: 9: 741.
4. Sehgal SN. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995: 17: 660.
5. Liu J, Farmer JD Jr., Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991: 66: 807.
6. Diekmann F, Waiser J, Fritsche L, Dragun D, Neumayer HH, Budde K. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc 2001: 33: 3234.
7. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001: 72: 777.
8. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999: 67: 1036.
9. Ruiz JC, Diekmann F, Campistol JM et al. Evolution of proteinuria after convesion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: A multicenter study. Transplant Proc 2005: 37: 3833.
10. Boratynska M, Banasik M, Watorek E et al. Conversion to sirolimus from cyclosporine may induce nephritic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006: 38: 101.
11. Kushwaha SS, Khalpey Z, Frantz RP et al. Sirolimus in cardiac transplantation: Use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. J Heart Lung Transplant 2005: 24: 2129.
12. Kniepeiss D, Iberer F, Grasser B, Schaffellner S, Tscheiliessnigg KH. Sirolimus in patients after liver transplantation. Transplant Proc 2003: 35: 815.
13. Neff GW, Montalbano M, Slapak-Green G et al. Sirolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc 2003: 35: 3029.
14. Sanchez EQ, Martin AP, Ikegami T et al. Sirolimus conversion after liver transplantation: Improvement in measured glomerular filtration rate after 2 years. Transplant Proc 2005: 37: 4416.
15. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002: 8: 128.
16. Zhu J, Wu J, Frizell E et al. Rapamycin inhibits stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology 1999: 117: 1198.
17. Trotter JF, Wachs M, Bak T et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001: 7: 343.
18. Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopoic liver transplant recipients. Transplant Proc 2003: 35: 209S.
19. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol 1989: 129: 125.
20. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: Evaluation of current equations. Liver Transpl 2004: 10: 301.